Health Care/Hospital

MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform

BOSTON, July 3, 2025 /PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment ofMaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer. The move comes as MOTE accelerates development of its MOBILIZ...

2025-07-03 18:07 2042

Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy

HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispec...

2025-07-03 14:46 2135

Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

* ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR  exon20ins * Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningfulbenefits to patien...

2025-07-03 08:08 2119

Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001

Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...

2025-07-03 07:09 1966

Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30

-  First participants with obesity or overweight with at least one weight-r elatedcomorbidity have been dosed in a U.S. 13-week Phase IIa study of small m oleculeoral GLP-1 receptor agonist ASC30. -  ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean  body weight reduction f...

2025-07-03 07:00 2100

SeekInClarity: Blood-Based Multi-Omics Test Offers Promising Advance in Monitoring Cancer Treatment Response

SAN DIEGO, July 2, 2025 /PRNewswire/ -- A new prospective study published in BMC Cancer demonstrates that a novel blood-based multi-omics test, SeekInClarity, can accurately assess and predict therapeutic outcomes in lymphoma patients across different subtypes—potentially transforming how clinic...

2025-07-02 23:00 1978

Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis

SEOUL, South Korea, July 2, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions. In conjunction with their recent acquisition of V...

2025-07-02 21:00 2207

[iNtRON] Files U.S. Patent for Three Novel Endolysin-Based Drug Candidates Targeting Gram-Negative Bacteria

* Gram-negative bacterial infections are becoming an increasingly serious global health issue * U.S. patent applications filed for three novel drug candidates: PKL200, TSL2200, and EAL2200 * Continued diversification of business initiatives to address Gram-negative bacterial threats BOSTON ...

2025-07-02 20:00 1863

Bon Announces Breakthrough Order for $16 Million Gut-Health Products

XI'AN, China, July 2, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solutions provider in the natural, health, and personal care industries, today announced a non-exclusive sales distribution agreement with Beijing Huahai Keyuan Te...

2025-07-02 20:00 3778

Arbele Wins Top Prize at BCIC's 4th Annual Biomedical Pitch Competition

BOSTON, July 2, 2025 /PRNewswire/ -- Arbele Limited, a Hong Kong-based biotech company, was awarded first place at the 4th Biomedical Pitch Competition, hosted by the Boston Capital Investment Club (BCIC). Selected from over 170 companies across the U.S. andAsia, Arbele stood out for its groundbr...

2025-07-02 16:19 1583

Declare Freedom from Discomfort This July -- Bestqool's Non-invasion Red Light Therapy

Let the light lead the way — this July, give yourself the freedom to feel your best. NEW YORK, July 1, 2025 /PRNewswire/ -- As the fireworks illuminate the night sky this 4th of July, Bestqool invites customers to celebrate independence not only as citizens but also within their own well-being j...

2025-07-01 22:08 2358

WuXi XDC Announces the Mechanical Completion of its Singapore Site, Accelerating the Global Expansion of Bioconjugates Manufacturing

SHANGHAI and SINGAPORE, July 1, 2025 /PRNewswire/ -- On June 30, WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, announced that the mechanical completion of its ma...

2025-07-01 17:44 4077

Pioneering Global Presence, Empowering the World - Zuowei Technology Shining at WHX Miami Medical Expo

SHENZHEN, China, July 1, 2025 /PRNewswire/ -- From June 11 to 13, the 2025 WHX Miami Medical Expo (formerly known as FIME), the annual grand event of the medical industry in the Americas, was held at theMiami Beach Convention Center. As one of the largest and most influential professional exhibit...

2025-07-01 16:32 2127

HanchorBio and Henlius Sign Major Licensing Deal for HCB101 to Expand Global Immuno-Oncology Reach

TAIPEI and SHANGHAI and SAN FRANCISCO, July 1, 2025 /PRNewswire/ -- HanchorBio Inc. (7827.TWO), a global clinical-stage biotechnology company developing innovative immunotherapies for oncology and autoimmune diseases, today announces the signing of a major out-licensing agreement with Shanghai He...

2025-07-01 13:40 1974

Affordable Ceretone OTC Hearing Aids Now Available at Target Stores Nationwide

LOS ANGELES, June 30, 2025 /PRNewswire/ -- Ceretone , a pioneering force in affordable hearing technology, today announces the nationwide launch of its over-the-counter (OTC) hearing aids at Target stores and Target.com. The company has established itself as a leading OTC h...

2025-06-30 22:30 1890

Noul Publishes Its Fifth Sustainability Report, Outlining a Vision for Growth and a Decade of Breakthroughs

* "The next decade will focus on securing strong growth momentum by strengthening product competitiveness and profitability" * First technology-special listed company to join the Corporate Value-Up Program… "We will grow by faithfully responding to stakeholder needs and expectations." YONGIN,...

2025-06-30 21:00 2054

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

Interim analysis planned for January 2026 with final trial results in late 2026 Highlights: * With the 100th participant enrolled in the XanaMIA trial, the timeline for the planned interim analysis is confirmed forJanuary 2026 and the timeline for final results reconfirmed for late 2026 * An...

2025-06-30 20:30 1664

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

TOKYO, June 30, 2025 /PRNewswire/ -- Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc.  ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance the global development of Astatine-211 (At-211) based radiopharmaceuticals. The collaboration co...

2025-06-30 20:00 1734

WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL

* The WuXiHigh™2.0 technology platform harnesses proprietary excipient blends and expertise to enable concentrations up to 230 mg/mL * It reduces viscosity by up to 90% while maintaining formulation stability and injectability SHANGHAI, June 30, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), ...

2025-06-30 19:00 3815

Smartee Unveils 'Live Update' to Slash Treatment Planning Time from Days to Seconds

SHANGHAI, June 30, 2025 /PRNewswire/ -- In an era where real-time treatment agility defines competitive orthodontic care, Smartee's Live Update has emerged as a game-changer for clear aligner workflows. Introduced inFebruary 2025, this new AI-powered feature on the SmarteeCheck platform is now al...

2025-06-30 15:48 1442
1 ... 28293031323334 ... 308